STAT

AUGUST 23, 2024

The comments came in response to an article  The Financial Times  that claimed the company is considered changing the location of a $578 million vaccine manufacturing plant from Liverpool to Philadelphia because the new U.K. and Japan, and have been in widespread use for mpox since 2022. to the U.S.

Vaccines 237

Vaccines Packaging 237

Pharmaceutical Technology

FEBRUARY 21, 2023

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast.

Vaccines 98

Vaccines 98

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. There are hopes that its mRNA approach, which proved so effective against COVID-19, could succeed where traditional vaccine technologies have failed in HIV.

Vaccines 145

Vaccines Immunity Immunization 145

STAT

APRIL 9, 2024

This is the largest amount raised since the first half of 2022 — and big news for an industry that has been icy for the last three years, once the attention the Covid pandemic brought to drug companies began to fade. Layoffs became commonplace. The company plans to submit the data to the U.S.

Vaccines 187

Vaccines 187

Pharma Times

JULY 27, 2021

Clinical trial for first vaccine candidate is planned for the end of 2022

Vaccines 123

Vaccines 123

pharmaphorum

JUNE 21, 2021

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot. Among the 25-strong group given the vaccine on its own, there was one patient who had a complete remission of tumours that had spread from the original site.

Vaccines 145

Vaccines Immunity Immunization 145

Express Pharma

JULY 2, 2024

Techinvention Lifecare has been appointed as a consultant by Botswana Vaccine Institute (BVI) to monitor setting up of the new cGMP compliant, vaccine manufacturing unit in its existing facility at Gaborone, Botswana. The project commenced in 2022 and is expected to be completed and operational by 2026.

Vaccines 111

Vaccines 111

Pharma Times

DECEMBER 14, 2021

The public have been assured more sites, mobile units and pop-ups would be set up across the country to fulfill the vaccination pledge ahead of the original deadline of 31 January 2022.

Vaccines 120

Vaccines 120

European Pharmaceutical Review

DECEMBER 22, 2022

has finalised a strategic partnership with the UK government to establish a state-of-the-art mRNA vaccine research, development, and manufacturing facility in the UK. This milestone follows the agreement in principle between Moderna and the UK Government, announced in June 2022. Moderna, Inc.

Vaccines 131

Vaccines 131

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccines 119

Vaccines Immunity Immunization 119

Pharmaceutical Technology

MARCH 28, 2023

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. In its FY 2022 report, BioNTech has identified herpes simplex virus (HSV), malaria, and shingles as disease targets. However, following its launch of the world’s first Omicron BA.4/BA.5

Vaccines 110

Vaccines 110

pharmaphorum

FEBRUARY 9, 2022

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front.

Vaccines 134

Vaccines Immunity Immunization Labelling 134

ALiEM - Pharm Pearls

JANUARY 12, 2024

A 42-year old Bengali man with a history of hyperlipidemia presented to the Emergency Department with facial swelling, diffuse rash, renal insufficiency and proteinuria after receiving his COVID-19 vaccine (Moderna) booster dose. Erythema multiforme has been reported as a cutaneous reaction after the COVID-19 mRNA vaccine.

Vaccines 130

Vaccines 130

Pharma Times

DECEMBER 15, 2023

The funding builds on AstriVax’s €30m in seed funding for its vaccine platform AstriVax has announced that it has been awarded a total of €3m in funding from Flanders Innovation & Entrepreneurship (VLAIO) for its therapeutic vaccine targeting chronic hepatitis B. in May to advance the company’s innovative vaccine platform.

Vaccines 120

Vaccines 120

European Pharmaceutical Review

MAY 9, 2024

Withdrawal of the marketing authorisation for the COVID-19 vaccine (ChAdOx1-S [recombinant]) Vaxzevria (SRD) by the European Medicines Agency on 7 May, follows a request by AstraZeneca. Global demand for all COVID vaccines is now much lower and overall supply exceeds demand.

Vaccines 110

Vaccines 110

European Pharmaceutical Review

AUGUST 2, 2023

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax is now the ninth vaccine to be authorised by the UK’s independent medicines regulator to treat the virus. The vaccine demonstrated a strong immune response in the trial.

Vaccines 98

Vaccines Immunity Immunization 98

Express Pharma

JUNE 15, 2023

The current influenza vaccines only provide protection against a limited number of strains, with the strains predicted to be dominant in the upcoming season selected for inclusion in the vaccines. Ultimately one of the biggest benefits of a universal influenza vaccine is that it could help to contain a potential pandemic.”

Vaccines 98

Vaccines Immunity Immunization Hospitals 98

pharmaphorum

AUGUST 12, 2021

The UK government has started ordering COVID-19 vaccines for a 2022 booster campaign, including a 32 million-dose order for the Pfizer/BioNTech shot, even before third doses for 2021 have been given the go-ahead. The Johnson & Johnson vaccine is also supplied on a no-profit basis. Pricing slammed.

Vaccines 111

Vaccines Immunity Immunization 111

pharmaphorum

SEPTEMBER 15, 2021

The European Commission is reportedly in advanced discussions with French biotech Valneva about picking up the contract to supply COVID-19 vaccines that was terminated by the UK government this week. “Obviously she is not recommending that we administer vaccines that do not get approval,” said Javid.

Vaccines 116

Vaccines 116

The Pharmacist

MAY 4, 2023

Public health officials are urging parents to check their children are up to date with MMR vaccinations after signs of a rise in measles cases.

Vaccines 93

Vaccines 93

pharmaphorum

JANUARY 19, 2023

Biotech Vaxxas has announced a partnership agreement with the 2017-established Coalition for Epidemic Preparedness Innovations (CEPI), in order to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology with preclinical testing of an mRNA vaccine patch. The agreement, worth $4.3 The agreement, worth $4.3

Vaccines 105

Vaccines Immunity Immunization 105

European Pharmaceutical Review

AUGUST 16, 2022

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated version of Moderna’s COVID-19 vaccine, Spikevax, that targets two coronavirus variants as a booster. The regulator confirmed that the vaccine meets its standards of safety, quality and effectiveness. 1) and the original 2020 strain.

Vaccines 105

Vaccines Immunization Immunity 105

The Pharmacist

AUGUST 9, 2023

Community pharmacies are most likely to fund split-sector roles in Covid vaccination clinics, general practice and primary care networks (PCNs), a recently published workforce survey has suggested.

Vaccines 98

Vaccines Community Pharmacies 98

European Pharmaceutical Review

FEBRUARY 13, 2023

and BioNTech SE have announced the start of a Phase I/II trial for the companies’ mRNA vaccines for shingles (Herpes Zoster), for which there is no currently approved vaccine. Without vaccination, about half of the people who live to age 85 are expected to develop shingles, stated BioNTech. Pfizer Inc.

Vaccines 105

Vaccines 105

Pharmaceutical Technology

JULY 1, 2022

Some months after the first Covid-19 vaccines became available, the World Health Organization (WHO) set a target of vaccinating 70% of each country’s population by the end of June 2022. The post Magazine-How delays derailed Covid-19 vaccination in Africa appeared first on Pharmaceutical Technology.

Vaccines 110

Vaccines 110

Pharmaceutical Technology

JUNE 9, 2023

5+delta) protein vaccine (Sf9 cell). This marks the world’s first Covid-19 vaccine approved for emergency use against XBB descendent lineages of SARS-CoV-2. The vaccine has been developed by WestVac Biopharma along with the West China Medical Center and Sichuan University. recombinant Covid-19 trivalent (XBB.1.5+BA.5+delta)

Vaccines 107

Vaccines 107

European Pharmaceutical Review

NOVEMBER 3, 2022

GSK has announced the European Medicines Agency (EMA) has validated a marketing authorisation application (MAA) under accelerated assessment for its respiratory syncytial virus (RSV) vaccine for adults above 60. If approved, the vaccine could be the first vaccine to prevent RSV lower respiratory tract disease (LRTD) in older adults.

Vaccines 105

Vaccines 105

European Pharmaceutical Review

DECEMBER 2, 2022

Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine. Improve access and convenience to immunisation for adults.

Vaccines 98

Vaccines Immunity Immunization 98

Pharmaceutical Technology

DECEMBER 11, 2022

The US Food and Drug Administration (FDA) has granted Fast Track designation for Pfizer and BioNTech’s messenger ribonucleic acid (mRNA)-based combination vaccine candidate against Covid-19 and influenza. The vaccine is intended to prevent two respiratory ailments through a single injection. 5 Omicron sublineages spike proteins.

Vaccines 115

Vaccines Communication 115

pharmaphorum

JUNE 9, 2022

Moderna’s new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company’s original Spikevax shot in a head-to-head clinical trial. It has predicted sales of COVID-19 vaccines will be around $21 billion this year. Three-month data will be reported later this summer.

Vaccines 105

Vaccines 105

Digital Pharmacist

AUGUST 16, 2022

On August 9th, 2022, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the JYNNEOS vaccine. Here is what you need to know about the monkeypox vaccine emergency use authorization. . JYNNEOS Vaccine Authorization Details . Background of the JYNNEOS Vaccine.

Vaccines 98

Vaccines 98

pharmaphorum

SEPTEMBER 28, 2021

Prospects for Valneva’s COVID-19 vaccine are up in the air, but another candidate partnered with Pfizer looks increasingly like it could fill the void of an effective shot for Lyme disease. billion contract to supply up to 100 million doses of its COVID-19 vaccine VLA2001.

Vaccines 105

Vaccines 105

pharmaphorum

OCTOBER 7, 2021

Moderna has said it plans to invest $500 million in a new facility for manufacturing mRNA vaccines in Africa, and has kicked off a search to find a suitable country and location. of Africans have been fully vaccinated against COVID-19, and just 15 African nations have met the agency’s objective of 10% coverage.

Vaccines 98

Vaccines Packaging 98

Pharmaceutical Technology

AUGUST 17, 2022

On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. In June 2022, Pfizer acquired 8.1% This means that the vaccine works against multiple serotypes of the disease, she explains.

Vaccines 119

Vaccines 119

European Pharmaceutical Review

AUGUST 22, 2022

THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. Novel biotechnology platforms for vaccine development.

Vaccines 98

Vaccines Immunity Immunization 98

pharmaphorum

OCTOBER 12, 2022

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. As we all know, cancer vaccines have had a rough history. — Brad Loncar (@bradloncar) October 12, 2022. — Brad Loncar (@bradloncar) October 12, 2022.

Vaccines 105

Vaccines 105

Pharmaceutical Technology

MAY 2, 2023

4/5 Covid-19 messenger RNA (mRNA) vaccines. The expanded EUAs state that these current bivalent vaccines are now to be used for all primary and booster doses administered to individuals ages six months of age and older. 1 vaccines by both companies were revoked by the FDA in August 2022, after the BA.5

Vaccines 21

Vaccines Immunity Immunization 21